Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 2 Diabetes Mellitus: early-phase trial registry
15 of 131 indexed Type 2 Diabetes Mellitus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #91 of 28,707 conditions by registered trial count.
131 US clinical trials · 15 currently recruiting · #91 of 28,707 conditions by registered trial count
Type 2 Diabetes Mellitus: 131 US clinical trials tracked, 15 recruiting.
Type 2 Diabetes Mellitus is the subject of 131 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.
Enrollment posture brief
Registry condition type-2-diabetes-mellitus
OPEN 15 | RECR 11% | LATE 26 | EARLY 52 | RANK #91 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Actinic Keratosis (12% recruiting · 17 trials)
Type 2 Diabetes Mellitus lists 15 open slots (11% of 131 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 2 Diabetes Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 2 Diabetes Mellitus is recruiting below its size-band peers.
15 of 131 indexed trials (11.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 2 Diabetes Mellitus trials is spread across many organizations.
AstraZeneca accounts for 11 of 131 trials (8.4%). 82 distinct sponsors appear on at least one study for this condition label.
-
Typical Type 2 Diabetes Mellitus enrolment sits around 70 participants.
Median target enrolment is 70 among the 131 trials that report a genuine target (sentinel values excluded). 76 of those (58%) plan for fewer than 100 participants.
-
Type 2 Diabetes Mellitus research is mostly interventional.
116 interventional and 15 observational studies make up this index (88.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
131 total, page 1 of 3
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Bayer
NCT06278207
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
NCT07351058
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Prokidney
NCT05099770
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Medtronic Diabetes
NCT07228117
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Endogenex
NCT06267391
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
Hoffmann-La Roche
NCT07112872
The GRoceries Aimed at Increasing Nutrition Study
University of Pennsylvania
NCT07167004
Preventing Type 2 Diabetes in Black Emergent Adult
University of North Carolina, Chapel Hill
NCT06848244
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Petter Bjornstad
NCT05008276
Regulation of Endogenous Glucose Production by Central KATP Channels
Meredith Hawkins
NCT03540758
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
Amgen
NCT07160257
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
Joslin Diabetes Center
NCT05754281
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Yale University
NCT05067621
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Eli Lilly and Company
NCT06362265
A Study of Glycemic Control in Left Ventricular Assist
Mayo Clinic
NCT05933161
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
Bayer
NCT06608212
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Bayer
NCT05348733
Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study
University of California, Davis
NCT01817127
Behavioral Chronotype: Impact on Sleep and Metabolism
University of Chicago
NCT03647306
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
VA Office of Research and Development
NCT03887936
Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes
Baltimore VA Medical Center
NCT01176578
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
University of Pittsburgh
NCT01047735
Effort During Resistance Training in Type 2 Diabetes
University of New Mexi
NCT06497842
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans
Joslin Diabetes Center
NCT03860558
An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes
Insulet Corporation
NCT07276776
GLP-1 and Hypoglycemia
University of Maryland, Baltimore
NCT01858896
Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose
University of New Mexi
NCT06208189
Impact of Medicaid Health Home on Patients With Diabetes in New York City
Icahn School of Medicine at Mount Sinai
NCT02713321
Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
Brigham and Women's Hospital
NCT07203677
Improving Diabetes in Primary Care (IMPACT)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00108927
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
NCT06065540
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Takeda
NCT00856284
Study of Rivoglitazone in Type 2 Diabetes Mellitus
Daiichi Sankyo
NCT00484198
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Bayer
NCT05254002
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
AstraZeneca
NCT00229658
Detection of Ischemia in Asymptomatic Diabetics
Yale University
NCT00769275
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Gilead Sciences
NCT01425359
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
Sanofi
NCT01676220
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
AstraZeneca
NCT02551874
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
PhaseBio Pharmaceuticals
NCT01658501
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Lexicon Pharmaceuticals
NCT03285594
Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being
Scripps Whittier Diabetes Institute
NCT02723019
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes
AstraZeneca
NCT00736879
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Hanmi Pharmaceutical Company Limited
NCT03353350
Welchol as Monotherapy for Type 2 Diabetes Mellitus
Daiichi Sankyo
NCT00789737
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
Medtronic Diabetes
NCT04436822
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
Lexicon Pharmaceuticals
NCT01376557
Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes
University of Chicago
NCT03487692
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
TWi Biotechnology
NCT01276106
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
AstraZeneca
NCT00877890
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 23 |
| Phase 3 | 16 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 2 Diabetes Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 2 Diabetes Mellitus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 2 Diabetes Mellitus page
131 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Type 2 Diabetes Mellitus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Type 2 Diabetes Mellitus trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes Mellitus condition card totals 131 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.